eShowcase: Liquent InSight v. 3.5
Dual-purpose package allows submission in both paper and electronic formats
Dual-purpose package allows submission in both paper and electronic formats
Thomson Scientific (Philadelphia, PA, and London, UK) recently released the latest version of its regulatory compliance tool, InSight Publisher version 3.5. The latest iteration enables pharmaceutical companies to create, manage, and publish regulatory submissions in both paper and electronic form using a single software application, potentially saving critical time in the drug development process.
Around the world, regulatory authorities increasingly prefer the electronic format, yet they still require a paper version. With Liquent InSight version 3.5, life science professionals can produce both from a single assembly, using the same thin-client application integrated with the rest of the InSight software suite. Since it is built on the same platform as InSight Manager, which offers registration management and submission tracking capabilities, the entire platform is highly adaptable to different organizational processes and designs.
Thomson Scientific, (215) 386-0100, www.liquent.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
